Zentalis : Focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral SERD for estrogen receptor positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Anthony Sun
Zentalis, CEO
Anthony has played an active role across the life science industry since 2002 and currently serves as Chief Executive Officer for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund, private equity firms dedicated to the life sciences, during which he held multiple positions most recently as Partner. Dr. Sun holds a BS in Electrical Engineering from Cornell University, an MD from Temple University School of Medicine, an MBA from The Wharton School at the University of Pennsylvania. He trained in internal medicine at the Hospital of the University of Pennsylvania and was board certified in internal medicine.

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication Phase
Breast Cancer 1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication Phase
Solid Tumors 1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication Phase
NSCLC 1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Viking Global Investors LP 12.38 4,443,284 202.04 Stakes 2020-04-07
Matrix Capital Management Co. LP 10.65 3,821,739 173.77 Stakes 2020-04-03
Tybourne Capital Management (HK) Ltd. 7.43 2,664,409 121.15 Stakes 2020-05-29
Citadel Advisors LLC 5.94 2,129,964 96.85 Stakes 2020-04-03
Fidelity Management & Research Co. LLC 4.66 1,671,977 76.02 Funds 2020-04-30
AllianceBernstein LP 0.64 228,755 10.40 Funds 2020-04-30
Polar Capital LLP 0.42 150,000 6.82 Funds 2020-04-30
Franklin Advisers, Inc. 0.21 73,700 3.35 Funds 2020-05-31
The Vanguard Group, Inc. 0.08 28,894 1.31 Funds 2020-05-31
Bridgeway Capital Management, Inc. 0.00 1,260 0.06 Funds 2020-04-30
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.